Prostate Cancer Clinical Trial
— PROLIPSYOfficial title:
Early Detection of Prostate Cancer by Liquid Biopsy
This study is the early detection of prostate cancer by analysing circulating bloodbased biomarkers. Based on our latest developments, we primarily aim to assess the validity of CTCs (circulating tumour cells) and tumour cell products circulating in blood (DNA, exosomes) for early PCa (Prostate cancer) detection. In the first discovery period, the investigators will assess which Liquid biopsy marker will provide the best discrimination between the patients with histologically proven PCa and age-matched noncancer controls. Further subset analysis with special emphasis on the identification of high risk PCa patients with aggressive tumours as defined by a Gleason score ("gold standard") of 8 or higher (ISUP 4 and higher), will be performed. The resulting biomarker candidates will then be further explored in the subsequent training and validation study (years 2 and 3) in order to obtain the single blood test or combination of tests with the highest sensitivity and specificity for detection of early PCa and/or high-risk PCa. The investigators will also compare these new biomarkers with recently FDA cleared CE-IVD assays for early detection of prostate cancer, based on classic peripheral tumour markers, such as Prostate Health Index (PHI) and PCA3. Follow up evaluations will be initiated to assess the prognostic relevance of the candidate biomarkers determined in this project. Here, the investigators will set up the data management system including all relevant information on the tissues collected and the results of the analyses as well as the clinical data of the patients investigated in this study.
Status | Recruiting |
Enrollment | 320 |
Est. completion date | September 15, 2033 |
Est. primary completion date | November 15, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria Patient : - Men over 40 being suspicious of prostate cancer - Subject with PSA = 4 and designated for biopsy - Subjects must be able to attend all scheduled visits and to comply with all trial procedures - mpMRI done before prostate biopsy - Subject must be covered by public health insurance - Signed informed consent form Inclusion Criteria Subject Control Patient patient free from prostatic disease : - Men over 40 with no suspicion of prostate cancer - Subject with PSA < 2.5 and normal digital rectal examination - Subject must be covered by public health insurance - Signed informed consent form Exclusion Criteria Patient : - Subject with histologically confirmed prostate cancer - Subject with a verified viral infection (HIV or Hepatitis) - Subject under Finasteride treatment - Subject under hormonal treatment (analogs, antagonists, androgenics) - Subject with other cancer diagnosed - Subject unable to sign consent - Planned longer stay outside the region that prevents compliance with the visit plan - Subject deprived of liberty, protected adults or vulnerable persons - Urinary infection = 2 months - Subject excluding health insurance registration - Subject refusing to perform prostate biopsy - Subject who are in a dependency or employment with the sponsor or the investigator Exclusion Criteria Subject Control : - Subject with histologically confirmed prostate cancer - Subject with a verified viral infection (HIV or Hepatitis) - Subject under Finasteride treatment - Subject with other cancer diagnosed - Subject unable to sign consent - Planned longer stay outside the region that prevents compliance with the visit plan - Subject deprived of liberty, protected adults or vulnerable persons - Urinary infection = 2 months - Subject excluding health insurance registration |
Country | Name | City | State |
---|---|---|---|
France | CHU Montpellier - Département d'urologie et transplantation rénale | Montpellier | |
France | CHU Montpellier - Laboratoire des Cellules Circulantes Rares Humaines | Montpellier | |
France | Clinique Beau Soleil - Service d'urologie | Montpellier | |
France | CHU de Nîmes - Service Urologie Andrologie Sexologie | Nîmes |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Discovery of CTCs and tumour cell products circulating in blood (DNA, exosomes) for early PCa detection. | Evaluate Liquid biopsy marker between the patients with histologically proven PCa and age-matched noncancer controls. | Expected duration of the recruitment of the discovery phase: 12 months | |
Secondary | Detection duration of the recruitment of the validation study. | The most marker(s) assay(s) will be further explored in the subsequent training and validation study in order to obtain the blood test to detect early prostate cancer in patients with elevated serum PSA. | Expected duration of the recruitment of the validation study: 24 months | |
Secondary | Validity of blood test with the highest specificity for detection of early PCa and/or high-risk PCa. | Combination of complementary circulating biomarkers as liquid biopsy of cancer (CTCs, circulating tumor DNA & exosomes). | Expected duration of the recruitment of the validation study: 24 months | |
Secondary | Validity of blood test with the highest specificity for detection of early PCa and/or high-risk PCa. | Measure the prognostic relevance of candidate biomarkers | Expected duration of the recruitment of the validation study: 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |